New drug combo shows promise against tough esophageal cancer
NCT ID NCT04229459
First seen Jan 19, 2026 · Last updated May 23, 2026 · Updated 20 times
Summary
This study tested whether adding two drugs, nivolumab and cetuximab, to standard chemoradiation helps shrink advanced esophageal cancer before surgery. Twelve people who had not been treated before took part. The goal was to see if the cancer completely disappeared after treatment. The study is no longer recruiting, and results will show how safe and effective this approach is.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Rabin Medical Center
Petah Tikva, Israel
Conditions
Explore the condition pages connected to this study.